Hematologic Malignancy
Tumors Derived from Langerhans Cells
CI-CAN-00001621Explore in graph →
HematologicNon-malignant12 active trials2 evidence items
- NCIt
- C150692
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001621Explore in graph →
Clinical trials
27 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05915208 | Histiocytic Disorder Follow-up Study | recruiting | — | 6,000 | University of Alabama at BirminghamOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06712810 |
Data updated 22 days agoSource updated Aug 25, 2026source: clinicaltrials
| Q702 for the Treatment of Patients With Hematologic Malignancies |
| recruiting |
| Phase 1 |
| 46 |
| Mayo ClinicOTHER |
| 1 |
| Oct 10, 2025 |
| clinicaltrials |
| NCT04079179 | Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders(NACHO-COBI) | recruiting | Phase 2 | 90 | Carl AllenOTHER | 1 | Sep 18, 2025 | clinicaltrials |